The most prominent form of synovial joint disease, osteoarthritis (OA), is characterized
by joint degeneration, pain, and in some patients, articular neuropathy. Chronic pain
associated with OA is a major concern for which there are few viable treatments. The first line
therapy used to treat OA pain is non-steroidal anti-inflammatory drugs (NSAIDs); however, with
long-term use their efficacy declines and they can lead to major adverse gastrointestinal and
cardiovascular events. Historically, OA has been classified as a non-inflammatory arthritis;
however, there is now overwhelming evidence that synovitis can occur in response to proinflammatory
mediators being released into the joint. It is believed that this low-level inflammation contributes to degenerative changes that affect the entire joint leading to the development of peripheral sensitization and nociceptive pain . In addition to structural defects, there is growing evidence to suggest that approximately 30% of OA patients suffer from neuropathic pain. Thus, a therapeutic which can block inflammation, neuropathy, and pain is sorely needed.
The endocannabinoid system (ECS) plays an important physiological role in the
regulation of tissue inflammation and pain. A functional ECS has been demonstrated in
the joints of animals and humans, which acts tonically to maintain joint homeostasis.
Immunohistological and pharmacological evidence confirm that cannabinoid 1 (CB1) and
cannabinoid 2 (CB2) receptors are expressed on the neurones and microvasculature that supply
rat knee joints. Additionally, CB2 receptors are co-localized with pronociceptive
transient receptor potential vanilloid-1 (TRPV1) channels where, through common intra-cellular
pathways, they act together to modulate joint pain. This suggests that drugs which
target the ECS have the potential to regulate painful arthritis and inflammatory joint disease.
Cannabidiol (Hemp) is the main non-euphoria producing component of the cannabis plant.
Pharmacologically, Hemp has a complex signalling mechanism whereby it can both activate
and silence classical cannabinoid receptors as well as modulate non-canonical cannabinoid
receptor pathways. In in vitro studies, Hemp has been shown to be an inverse agonist at CB2
receptors, and a full antagonist at CB1 receptors and G protein-coupled receptor-55
(GPR55). In vitro, Hemp was found to be an agonist at TRPV1 and transient receptor
potential ankyrin 1 (TRPA1), which play a central role in the development of OA. In
musculoskeletal disease models, systemic administration of Hemp suppressed the progression of
collagen-induced arthritis by reducing inflammatory cytokine production. While these
preliminary findings indicate a possible role for Hemp in relieving joint inflammation, the local
effect of articularly applied Hemp on OA and joint pain has not been investigated.
The initial aim of the present study was to assess the effect of locally administered Hemp
on joint pain in animals with end-stage OA. Since acute inflammation can contribute to the
long-term development of OA joint pain, the ability of Hemp to reduce acute OA synovitis
and prevent the subsequent progression of chronic persistent OA pain was also investigated.
Finally, the effect of prophylactic Hemp treatment on OA joint neuropathy was assessed by the authors.
Hemp Inc (OTCMKTS:HEMP) Looks to Garner Support on Expansion and CBD Talk
Hemp Inc (OTCMKTS:HEMP) shares recently slipped under technical support in the $0.025. The stock has possibly found some bids in...
How to View the Current Action in Hemp Inc (OTCMKTS:HEMP)
One stock that has started to key on potential support in a lateral range is Hemp Inc (OTCMKTS:HEMP). The stock...
Near-Term Headwinds Hit Scotts Miracle-Gro Co (NYSE:SMG) With A Huge Impact
Bank of America Corp (NYSE:BAC) has disclosed that Scotts Miracle-Gro Co (NYSE:SMG) has lately been experiencing several near term risks....
Argitek Holdings Inc (OTCMKTS:AGTK) To Focus On Acquisition, Revenues & Profitability In 2018
Argitek Holdings Inc (OTCMKTS:AGTK) recently revealed that in 2018, the company’s main focus will be the acquisition, revenues, and profitability....
PharmaCyte Biotech Inc (OTCMKTS:PMCB) Completes Pore Size Studies & 29 Tests Useful In Pancreatic Cancer Therapy
PharmaCyte Biotech Inc (OTCMKTS:PMCB) has said that the cells it is planning to use in the clinical trial in patients...
Puration Inc (OTCMKTS:PURA) To Apply For Canadian Recreational Cannabis Cultivation License; To Give EVERx CBD Sports Water Free Samples
Puration Inc (OTCMKTS:PURA) recently announced that it will be applying for the Canadian recreational cannabis cultivation license. The confirmation came...
Marijuana Company Of America Inc (OTCMKTS:MCOA)’s JV Completes 10,000 Sq. Ft. Greenhouse Set up; Provides Update on Oregon Project
Marijuana Company Of America Inc (OTCMKTS:MCOA) recently announced that its Joint Venture with Bougainville Ventures Inc. based in Washington has...
Lifestyle Delivery Systems Inc.(OTCMKTS:LDSYF)’s CSPA Group Inc. Receives 15000 Reveur Units & 300 Liters Distillates’ Purchase Orders In Two Different Deals
Lifestyle Delivery Systems Inc. (OTCMKTS:LDSYF) recently made two big announcements related to the receipt of two open purchase orders to...
Viaderma Inc (OTCMKTS:VDRM) Provides Update On Its Flagship Product Vitastem; Signs $250,000 Agreement With Vage Nigeria Ltd.
Viaderma Inc (OTCMKTS:VDRM), a publicly traded specialty pharmaceutical company recently announced an update on the sales of its flagship product...
Plandai Biotechnology Inc (OTCMKTS:PLPL) Phytofare Gaining Traction in International Markets
Plandai Biotechnology Inc (OTCMKTS:PLPL) recently issued an update following the successful launch of its Phytofare® supplement. Plandai Biotechnology is a...